In December, the "PUMCH-GENESIS" AI Hospital Research Institute evolved from diagnostic assistance to a new ecosystem for AI ...

On March 26, local residents will have the opportunity to receive free genetic testing at Health Quest. The non-invasive cheek-swab tests will examine participants’ DNA by checking for 84 genetic ...

New research has been published ahead-of-print by The Journal of Nuclear Medicine (JNM). JNM is published by the ...

Networked models of care have the potential to provide better access to specialist care for rare diseases in the NHS. The government committed to establishing an innovative networked model of care for ...

HAELO Phase 3 clinical data for lonvo-z in HAE expected by mid-2026; BLA submission in second half of 2026; anticipated U.S. launch in first half of 2027Process underway to reactivate global sites for ...

HAELO Phase 3 clinical data for lonvo-z in HAE expected by mid-2026; BLA submission in second half of 2026; anticipated U.S. launch in first half ...

Gene therapy and gene editing are marvels of modern biotechnology, providing revolutionary techniques for fixing genetic abnormalities. Gene therapy introduces functional genetic material to ...

Researchers have identified a natural compound from pomegranate leaves and branches that can directly dismantle the protein aggregates responsible for transthyretin amyloidosis.

Researchers identified PGG, a pomegranate compound, as an amyloid disruptor that breaks down toxic transthyretin aggregates.

BridgeBio Pharma (NASDAQ:BBIO) executives used the company’s fourth-quarter 2025 earnings call to highlight accelerating commercial performance for its transthyretin amyloid cardiomyopathy (ATTR-CM) d ...

BridgeBio Pharma Inc. (NASDAQ:BBIO) reported fourth quarter revenue of $154.2 million, exceeding analyst estimates of $146.16 million, though the company posted a wider-than-expected loss. The ...

A research team at Kumamoto University has discovered that a natural compound found in pomegranate leaves and branches can ...